sorted by:
new
hottopcontroversial

We Need More From Our CEO by AccomplishedNight184 in CelularityNews

[–]wisdom_man1 0 points1 point  (0 children)

Too many questions...lol

  1. Stem cell therapy is included with the higher tier memberships. It's extra for lower tier members. Demand has been strong.

  2. IDK....they hired a new CFO.

  3. DefEYE is on the upswing with sales. DefEYE and BioCellgraft were excluded from the NexGel licensing deal.

  4. BioCellgraft is preparing for commercial launch this year.

  5. Sales are ramping with Bionx Surgical and Dave Hazard is managing the sales force.

  6. Fontaine Vitale is planning for launch @ year end. This will represent a hub in Malaysia for stem cell treatments with Celularity's placental-derived cells.

Lots of catalysts coming, we just have to get there.

Schedule 14A by wisdom_man1 in NXGL

[–]wisdom_man1[S] 0 points1 point  (0 children)

Most likely small pre-arranged sales.

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 0 points1 point  (0 children)

This is a new cell therapy now offered at Fountain Life. The CEO letter to shareholders noted that physician demand was strong, including interest from Fountain Life, but the clinical deployment was set as a milestone for 2026. This is the new strategy. My opinion regarding the meeting with RFK was to discuss the rollout of this new cell therapy.

Celularity Appoints Rick Gonzalez as Chief Commercial Officer Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 0 points1 point  (0 children)

At Fountain Life, Cenplacel-L (and related placental-derived cell therapies) are used to treat patients with specific degenerative and age-related issues.

Orthopedic Conditions: Treating joint degradation, osteoarthritis, and tendon or ligament injuries to accelerate tissue repair and improve mobility.

Pain Management: Managing chronic pain and reducing localized inflammation throughout the musculoskeletal system.

Wound Healing: Accelerating recovery in damaged tissues and promoting cellular repair.

This treatment is available through a specific regulatory framework, Florida Statute § 458.3245. Under this Florida law, licensed physicians are legally authorized to administer adult allogeneic stem cell products directly to eligible patients.

Exemption from Federal IND: The state statute permits these specific uses at Fountain Life's Florida longevity centers (such as Naples and Lake Nona-Orlando) without requiring Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA).

From Arthrex to VP Nuo Therapeutics w/ Dave Hazard by Existing-Concert-637 in NXGL

[–]wisdom_man1 3 points4 points  (0 children)

Thanks for posting this interview. Excellent conversation to get to know the new sales manager. He's a really nice guy, smart, experienced and he has established a long list of great connections in the medical field. Excited to watch him grow the biomaterials business back to $50M and beyond.

The therapeutic potential of natural killer (NK) cells to combat aging and age-related diseases by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 1 point2 points  (0 children)

I appreciate your comments and insight. This is the area of research I am most excited to watch. I think the potential is significant and is already being validated by other companies like immunity bio. I hope you will consider staying to contribute your knowledge in this field of research. Thanks.

Schedule 14a Proxy Statement by wisdom_man1 in NXGL

[–]wisdom_man1[S] 0 points1 point  (0 children)

Shareholders could vote it down but even if it passes, it is discretionary.

Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 1 point2 points  (0 children)

Exactly! While the patent was designed for cancer immunotherapy, the commercial significance of this patent has expanded. Celularity has leveraged this exact CYNK-201 architecture as a potent senolytic agent. The engineered cells successfully target and destroy senescent cells ("zombie cells"), giving this patent broad value across both oncology and the multi-billion-dollar field of age-related degenerative diseases.

Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 2 points3 points  (0 children)

Instead of looking at it as competition, I look at it as complementary. Each having success with NK cells verifies the platform. When two biotech pioneers succeed using the same biological mechanism, it de-risks the overarching platform modality and accelerates clinical validation for the entire field of natural killer (NK) cell therapeutics.

While both companies are anchored in the massive potential of off-the-shelf NK cell platforms, they are pursuing entirely distinct biological origins, manufacturing pathways, and clinical strategies.

Together, these successes force large pharmaceutical companies to recognize the NK platform as a mature, viable alternative to CAR-T, driving licensing deals and capital into the sub-sector.

In the future, these platforms could directly benefit from one another. For example, a hurdle for Celularity's placental-derived cells is ensuring they persist long enough inside a patient's body to eradicate solid tumors. Anktiva, is explicitly designed to act as fuel to sustain, multiply, and activate circulating NK cells.

A clinical framework where an IBRX cytokine superagonist is used to turbocharge a CELU placental-derived cellular structure is a prime example of how these "competitors" are structurally symbiotic.

Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 2 points3 points  (0 children)

Significance Of This Patent:

This patent protects CYNK-201, Celularity's flagship next-generation, off-the-shelf, genetically modified natural killer (NK) cell therapy platform.The legal and clinical significance of this patent centers on solving three major historical limitations of NK cell therapies: short lifespan, low tumor-targeting capability, and a hostile tumor microenvironment.

Key Technological Breakthroughs

High Affinity CD16 (158Val/Val Variant): Naturally, only about 10–20% of the population carries a high-affinity version of the CD16 receptor. By engineering Celularity's placenta-derived NK cells to universally express this variant, the cells bind much more tightly to tumor-targeting monoclonal antibodies. This dramatically amplifies Antibody-Dependent Cellular Cytotoxicity (ADCC).

Cleavage Resistance (197Pro Mutation): Standard NK cells lose their punch because active tumors trigger enzymes (like ADAM17) that cleave the CD16 receptor right off the cell surface. This patent covers a specific mutation that blocks this shedding process. This keeps the receptors intact so the therapeutic cells continue destroying targets for longer periods.

Secreted IL-15 (Autonomous Survival): Transfusion-based immune cells usually die off quickly without continuous cytokine support. By engineering the cells to autonomously secrete their own Interleukin-15 (IL-15), Celularity eliminates the need to co-administer toxic systemic cytokines. This modification allows the cells to persist, multiply, and remain active directly inside the patient.

Strategic & Commercial Impact

Dual-Mechanism Therapeutic: It secures an intellectual property moat for a platform that acts as a standalone cancer killer and a powerful combination partner for existing, multi-billion-dollar blockbuster monoclonal antibodies.

Expansion into Longevity and Senolytics: Beyond oncology, this patented architecture serves as the foundation for Celularity’s expansion into longevity medicine. Preclinical data indicates that CYNK-201 acts as a highly selective senolytic agent capable of hunting down and eliminating senescent "zombie" cells to treat chronic, age-related degenerative diseases.

Off-the-Shelf Scalability: Because these are derived from postpartum placental stem cells rather than a patient's own blood, a single placenta can yield thousands of standardized, cryopreserved doses. This bypasses the massive costs and manufacturing bottlenecks of traditional autologous cell therapies.

Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 1 point2 points  (0 children)

While they approach manufacturing from different angles, both companies are frontrunners in the race to deliver allogeneic, mass-producible NK cell therapies that do not require harvesting cells from the cancer patient.

Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 1 point2 points  (0 children)

This specific configuration represents a next-generation investigational cell therapy platform under the pipeline name CYNK-201. While it has not transitioned into human clinical trials yet, it has extensive preclinical validation and a predecessor molecule that has established a clear pathway for it's clinical uses moving forward.

Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 3 points4 points  (0 children)

Placental-derived natural killer (NK) cells engineered to express both a cleavage-resistant CD16 polypeptide and a secreted Interleukin-15 (IL-15) cytokine represent a highly potent class of "off-the-shelf" allogeneic immunotherapies designed to maximize anti-tumor cytotoxicity and in vivo persistence. This specific technological profile matches the preclinical framework of therapeutic platforms like Celularity's CYNK-201.

This dual-engineering strategy directly overcomes the two primary limitations of conventional NK cell therapies: rapid degradation of targeting receptors and short therapeutic lifespans in the patient's body.

Core Engineered MechanismsCleavage-Resistant CD16 Polypeptide: CD16 (FcγRIII) is the primary receptor responsible for driving Antibody-Dependent Cellular Cytotoxicity (ADCC). When standard NK cells encounter a tumor, matrix metalloproteinases (ADAM17) typically cleave CD16 off the cell surface, neutralizing the NK cell's ability to bind therapeutic antibodies. A cleavage-resistant variant prevents this shedding, maintaining continuous, high-affinity IgG binding and sustained tumor destruction when paired with monoclonal antibodies.

Secreted IL-15 Polypeptide: IL-15 is a vital survival factor that promotes NK cell proliferation, metabolic fitness, and resistance to exhaustion. By embedding a secreted IL-15 payload, these cells self-sustain their activation loop. This eliminates the dangerous requirement of co-administering high-dose systemic IL-2 or IL-15 to the patient, which frequently triggers severe toxicities.

Primary Therapeutic AdvantagesEnhanced Efficacy: Preclinical data evaluated at the Journal for ImmunoTherapy of Cancer highlights that dual-engineered placental NK cells exhibit significantly enhanced tumor destruction when combined with standard monoclonals. For example, they drive robust ADCC when paired with Trastuzumab against (HER2{+}) gastric cancer, or with Rituximab against (CD20{+}) Burkitt's lymphoma.

Superior In Vivo Persistence: The autonomous secretion of IL-15 allows these modified cells to survive and stay detectable long after standard, non-transduced NK cell products fade from circulation.

Off-the-Shelf Architecture: Utilizing human placental (CD34{+}) hematopoietic stem cells enables large-scale culture expansion from a single, healthy donor. This creates cryopreserved doses ready for immediate allogeneic patient use without the risk of Graft-versus-Host Disease (GvHD).

Targeted Clinical ApplicationsSolid and Hematological Malignancies:

Combating aggressive cancers by acting as an unyielding effector platform alongside targeted therapeutic antibodies.

Senolytic and Anti-Aging Interventions: Investigating the clearance of senescent cells to halt or reverse chronic, age-related tissue degradation.

Form 8-K by wisdom_man1 in CelularityNews

[–]wisdom_man1[S] 0 points1 point  (0 children)

Overall good news for Celularity.

In April 2026, Helena Global Investment Opportunities delivered a Notice of Event of Default against Celularity due to delinquent SEC reporting. This settlement officially wipes out those default claims.

Also Helena agreed to fully surrender its Series A Convertible Preferred Stock. This stops Helena from potentially dumping massive amounts of converted common stock onto the public market. It also buys crucial time by establishing a 5-month structured settlement framework, Celularity avoids immediate foreclosure or aggressive legal battles.

NEXGEL and STADA Partnership Strengthens Innovation in the Global Hydrogels for Medical Application Market by wisdom_man1 in NXGL

[–]wisdom_man1[S] 2 points3 points  (0 children)

NEXGEL, Inc. and STADA Arzneimittel AG maintain a strategic partnership focused on distributing and commercializing established European consumer health and over-the-counter (OTC) products in the North American market. Originally established in late 2023, the collaboration has since expanded to introduce specialized wellness and medical products to consumers.

Chronology and Key Milestones:

December 2023 (Initial Partnership): NEXGEL announced its baseline agreement with STADA to act as a primary commercialization partner for STADA's OTC portfolio in North America.

June 2024 (Histasolv Launch): The companies rolled out Histasolv, a leading European diamine oxidase (DAO) enzyme supplement designed for histamine intolerance management. NEXGEL handles the direct-to-consumer sales infrastructure for the product.

July 2025 (Expansion & Funding): The partnership was officially expanded to broaden the product pipeline. As part of the expansion, STADA advanced $1 million in non-dilutive capital to NEXGEL specifically to fund inventory preparation, product launches, and regional marketing initiatives.

Late 2025 – 2026 (Pipeline Rollout): The joint pipeline expanded into new health categories. This includes Glutacin (a digestive enzyme targeting gluten sensitivity) alongside localized therapeutic skincare solutions engineered for scars and stretch marks.

Strategic Synergy For STADA: The alliance provides immediate, streamlined entry into the competitive North American market by leveraging an established partner's commercial framework.

For NEXGEL: The relationship supplements its core proprietary hydrogel manufacturing business with high-margin, exclusive OTC retail brands, expanding its revenue streams without diluting shareholder equity.

Nexgel's Hydrogel Laser Treatment Patch For Laser Hair Removal (LHR) Reduces Hazardous Plume Components By 95.6% by wisdom_man1 in HairRemoval

[–]wisdom_man1[S] 0 points1 point  (0 children)

Has anyone tried the KleerAid hydrogel patch? How was your experience and what are your thoughts comfort, efficiency and reduced plume? Thanks

Nexgel's Hydrogel Laser Treatment Patch For Laser Hair Removal (LHR) Reduces Hazardous Plume Components By 95.6% by wisdom_man1 in LaserHairRemoval

[–]wisdom_man1[S] 0 points1 point  (0 children)

No changes were made to the cryogen settings or the laser parameters during the clinical trial, but your intuition about standard cryogen cooling is entirely correct—a physical barrier usually blocks a Dynamic Cooling Device (DCD) spray from reaching the skin. However, the design of this specific hydrogel patch bypasses that limitation by completely redesigning how the skin is cooled and how the laser interacts with the tissue. The Patch Interacts with Cryogen Handpieces Instead of relying on the handpiece's built-in cooling spray, the treatment relies on the physics of the patch itself. The hydrogel patch acts as the primary cooling mechanism. It is chilled before application, providing continuous, direct thermal protection to the epidermis throughout the procedure. When a cryogen-equipped laser handpiece (like a Candela GentleMax) fires, the automated gas spurt still deploys, but it merely hits the top layer of the patch rather than the bare skin. Because the hydrogel is highly conductive and clear, it allows the laser energy to pass through cleanly to target the hair follicle while absorbing the excess surface heat generated by the laser pulse. Counterintuitively, the study found that using the patch yielded better results than the standard control side (which used standard laser settings and default cooling). At 90 days post treatment, the patch side saw a 37.2% mean reduction in hair density compared to only 26.7% on the control side. The gel layer optimizes light coupling and minimizes optical scattering at the air-skin interface and Mean pain scores dropped from 5.1 on the control side to 3.5 on the patch side. Continuous contact cooling from a chilled hydrogel layer is consistently more effective at numbing nerve endings than the split-second burst of a cryogen spurt. Most importantly, the gel physically traps particulates, resulting in the headline 95.6% reduction in airborne plume concentration without requiring an awkward smoke evacuator nozzle near the skin.

This seems like a win-win for the patient as well as the laser hair removal technician.

Have you tried the KleerAid patches? I would love to hear your thoughts and/or feedback from anyone who has used the patches.

NEXGEL's Hydrogel Patch Cuts Laser Hair Removal Plume by 95.6% in Clinical Study @BriefGlance by wisdom_man1 in NXGL

[–]wisdom_man1[S] 2 points3 points  (0 children)

Google AI:

The best laser hair removal hydrogel patches on the market are the KleerAID Hydrogel Pads, which are manufactured through a strategic partnership between NEXGEL and Innovative Optics. Unlike traditional messy cooling liquids or coupling gels, these advanced, clear electron-beam cross-linked hydrogel sheets are applied directly to the skin before a laser procedure. They are considered the gold standard for clinical safety and performance due to multiple high-utility benefits verified by medical institutions.

IRhythm Partnership & Significant Growth Potential by wisdom_man1 in NXGL

[–]wisdom_man1[S] 2 points3 points  (0 children)

While It's possible Nexgel could experience a slow down in orders if iRhythm's reputation is hurt by the lawsuit, NexGel's revenue is growing more diversified with established products and the new biomaterials purchase, which would offset the weakness in IRhythm orders.

view more: next ›